3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
NCT07916337, Recruiting, Region Skane
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | 3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy | ClinicalTrials.gov |
| NCT number | NCT07916337 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 130 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Region Skane | ClinicalTrials.gov |
| Conditions | Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer, Cardiotoxicity, Echocardiography, Three-Dimensional | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in 3D left ventricular strain parameters compared with 2D global longitudinal strain during follow-up | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Relative change (%) from baseline in left ventricular strain parameters measured by 3D speckle-tracking echocardiography (global longitudinal strain, global circumferential strain, global radial strain and global area strain), compared with the relative change in global longitudinal strain measured by 2D speckle-tracking echocardiography in the same patients at each follow-up examination. | ClinicalTrials.gov |
| Secondary | Change in 3D left ventricular ejection fraction compared with 2D left ventricular ejection fraction | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Relative change (%) from baseline in right ventricular free wall longitudinal strain measured by speckle-tracking echocardiography. | ClinicalTrials.gov |
| Secondary | Change in right ventricular free wall longitudinal strain | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Relative change (%) from baseline in right ventricular strain (free wall and global longitudinal strain) and 3D right ventricular ejection fraction measured by echocardiography. | ClinicalTrials.gov |
| Secondary | Incidence of cancer therapy-related cardiac dysfunction (CTRCD) | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Proportion of participants developing asymptomatic or symptomatic CTRCD according to the 2022 ESC Cardio-Oncology Guidelines definitions, based on LVEF, 2D GLS and cardiac biomarkers. | ClinicalTrials.gov |
| Secondary | Area under the receiver operating characteristic curve of early change in 3D strain parameters for prediction of CTRCD | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Area under the receiver operating characteristic curve (AUC) for early relative change (%) in 3D left ventricular strain parameters measured by 3D speckle-tracking echocardiography, compared with 2D global longitudinal strain and left ventricular ejection fraction, for prediction of subsequent CTRCD according to the 2022 ESC Cardio-Oncology Guidelines. | ClinicalTrials.gov |
| Secondary | Correlation between change in 3D and 2D strain parameters and change in high-sensitivity troponin I | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Spearman correlation coefficient between the relative change (%) from baseline in left ventricular strain parameters measured by 3D speckle-tracking echocardiography (global longitudinal, circumferential, radial and area strain) and 2D global longitudinal strain measured by 2D speckle-tracking echocardiography, and the change from baseline in plasma concentration of high-sensitivity troponin I (ng/L), measured by laboratory immunoassay. | ClinicalTrials.gov |
| Secondary | Proportion of echocardiographic examinations with image quality adequate for 3D strain analysis | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Percentage of echocardiographic examinations in which image quality is adequate for analysis of left ventricular strain by 3D speckle-tracking echocardiography, compared with the percentage adequate for 2D speckle-tracking echocardiography. | ClinicalTrials.gov |
| Secondary | Correlation between 3D strain parameters and cardiac magnetic resonance measures | Up to 24 months after start of cancer therapy | Spearman correlation coefficient between left ventricular strain parameters measured by 3D speckle-tracking echocardiography (global longitudinal, circumferential, radial and area strain, %) and cardiac magnetic resonance measures: left ventricular ejection fraction (%), native T1 (ms), T2 (ms), extracellular volume (%) and extent of late gadolinium enhancement (% of left ventricular mass), in participants with and without evidence of cardiac injury. | ClinicalTrials.gov |
| Secondary | Number of participants with initiation of heart failure medication, hospitalisation for heart failure or all-cause death | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Number of participants with at least one of the following events: initiation of heart failure medication, hospitalisation for heart failure or death from any cause, retrieved from Region Skåne health records and national Swedish registers. | ClinicalTrials.gov |
| Secondary | Correlation between change in 3D and 2D strain parameters and change in NT-proBNP | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Spearman correlation coefficient between the relative change (%) from baseline in left ventricular strain parameters measured by 3D speckle-tracking echocardiography (global longitudinal, circumferential, radial and area strain) and 2D global longitudinal strain measured by 2D speckle-tracking echocardiography, and the change from baseline in plasma concentration of NT-proBNP (ng/L), measured by laboratory immunoassay. | ClinicalTrials.gov |
| Secondary | Change in 3D right ventricular ejection fraction | From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma) | Absolute change (percentage points) from baseline in right ventricular ejection fraction measured by 3D echocardiography. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)